交银医药创新股票C(014046)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
113,558,188.85 |
551,200,212.59 |
378,620,448.96 |
-478,146,401.85 |
| 利息合计 |
328,198.44 |
1,204,387.61 |
683,162.25 |
1,655,139.02 |
| 其中:存款利息收入 |
328,198.44 |
1,133,557.29 |
612,331.93 |
1,655,139.02 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
70,830.32 |
70,830.32 |
- |
| 投资收益合计 |
-59,402,104.42 |
410,993,237.31 |
56,030,738.74 |
-644,848,564.08 |
| 其中:股票投资收益 |
-68,159,010.68 |
392,742,474.71 |
40,247,900.45 |
-696,983,133.97 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
1,063,169.39 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
8,756,906.26 |
18,250,762.60 |
15,782,838.29 |
51,071,400.50 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
171,795,148.92 |
137,059,422.98 |
321,570,094.97 |
162,823,397.65 |
| 其他收入 |
836,945.91 |
1,943,164.69 |
336,453.00 |
2,223,625.56 |
| 费用 |
12,559,767.15 |
34,853,828.52 |
16,094,143.99 |
42,614,049.24 |
| 管理人报酬 |
10,471,653.56 |
29,234,025.79 |
13,447,619.70 |
35,095,471.90 |
| 基金托管费 |
1,745,275.60 |
4,872,337.65 |
2,241,269.98 |
5,849,245.26 |
| 销售服务费 |
248,764.86 |
557,439.46 |
310,866.54 |
1,469,441.36 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
94,073.13 |
189,770.64 |
94,132.79 |
199,887.82 |
| 利润总额 |
100,998,421.70 |
516,346,384.07 |
362,526,304.97 |
-520,760,451.09 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年